A Phase 1 open-label, proof-of-concept clinical trial of OTX-TIC in patients with glaucoma and ocular hypertension

Trial Profile

A Phase 1 open-label, proof-of-concept clinical trial of OTX-TIC in patients with glaucoma and ocular hypertension

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 May 2018

At a glance

  • Drugs Travoprost (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 03 May 2018 According to an Ocular Therapeutix media release, the company today announced the treatment of the first patient in a Phase 1 trial.
    • 03 May 2018 Status changed from planning to recruiting, according to an Ocular Therapeutix media release.
    • 27 Apr 2018 According to an Ocular Therapeutix media release, company plans to initiate clinical trials in the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top